Yu-Min Ko

 

YM Ko

Yu-Min Ko Assistant Professor

Office: U535  Extension: 2535
 E-mail：kym0115@tajen.edu.tw  

Projects│Journal Papers│Patent│Journal Reviewer│

    

Education: 

  1. Doctor of Philosophy (Ph.D.), Department of Biochemistry, Institute of Medicine, Kaohsiung Medical University

  2. Bachelor's degree, Department of Pharmacy, Kaohsiung Medical University

Current Positions:
  Tajen University, Department of Pharmacy and Master Program, Assistant Professor

Experience:

  1. Postdoctoral Researcher, Kaohsiung Medical University

  2. Assistant Researcher, Kaohsiung Medical University

  3. Assistant Researcher, Taiwan Instrument Research Institute, NARLabs.

  4. Adjunct Assistant Professor, I-Shou University

  5. Adjunct Assistant Professor, Meiho University

  6. Adjunct Assistant Professor, Chang Jung Christian University

Teaching Course:

   Pharmacology, biochemistry, molecular biology, biotechnology, biology, pathology,

   physiology, microbial immunology
 

 Projects：

  1. The association between trace elements and disease progression in chronic liver diseases
  2. Construct a type 2 Diabetes mouse model by gastrointestinal system-specific antioxidant gene knock-out mice
  3. The pathophysiological role of vitamin D in metabolic disorders in chronic hepatitis C virus infection
  4. Study on the regulatory mechanism of a metabolism-related hepatic gene A in mice
  5. Discovery of new therapeutic targets of liver for type 2 diabetes mellitus by comprehensively exploring the new pathogenetic mechanisms: A translational research linking bench, bioinformatics and clinics based on a model from chronic hepatitis C virus infection to general population / Study on the mechanisms of a diabetogenesis -related hepatic GeneA in mice
  6. To explore the impact of insulin resistance on NASH patients with interventional therapy
  7. To investigate the effect of TZD treatment on pathogenesis of NASH
  8. Investigation of  the efficacy of  sodium  glucose transporter-2 inhibitor and  dipeptidyl  peptidase-4 inhibitor in  the improvement of  mitochondrial function  in  non-alcoholic  steatohepatitis mouse model
  9. Development of precision agricultural health care products to prevent cardiovascular risks and metabolic syndrome
  10. Center of Excellence for Metabolic Associated Fatty Liver Disease

 Journal Papers：

  1. Ming-Ying Lu, Ta-Wei Liu, Po-Cheng Liang, Ching-I Huang, Yi-Shan Tsai, Pei-Chien Tsai, Yu-Min Ko, Wen-Hsuan Wang, Ching-Chih Lin, Kuan-Yu Chen, Shu-Chi Wang, Yu-Ju Wei, Po-Yao Hsu, Tyng-Yuan Jang, Ming-Yen Hsieh, Chih-Wen Wang, Ming-Lun Yeh, Zu-Yau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. (2023, Jan). Decision tree algorithm predicts hepatocellular carcinoma among chronic hepatitis C patients following viral eradication. American Journal of Cancer Research 2023;13(1):190-203. (Impact factor = 5.3)
  2. Po-Yao Hsu, Po-Cheng Liang, Wen-Tsan Chang, Ming-Ying Lu, Wen-Hsuan Wang, Shih-Chang Chuang,Yu-Ju Wei, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Yi-Hung Lin, Chih-Wen Wang, Ming-Yen Hsieh, Nai-Jen Hou, Meng-Hsuan Hsieh, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen,Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Wan-Long Chuang, Chung-Feng Huang, Jee-Fu Huang, Ming-Lung Yu. (2022, Dec). Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma. American Journal of Cancer Research 2022;12(12):5576-5588. (Impact factor = 5.3)
  3. Chun-Ting Chen,Tsai-Yuan Hsieh, Ming-Lun Yeh, Ching-I Huang, Yi-Shan Tsai, Yu-Min Ko,Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, ChengTing Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, ZuYau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Yu-Lueng Shih, Ming-Lung Yu. (2022, Jan). Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.World Journal of Gastroenterology, 28(2):263- 274. (Impact factor = 5.28)
  4. Ming-Ying Lu, Ming-Lun Yeh, Ching-I Huang, Shu-Chi Wang, Yi-Shan Tsai, Pei-Chien Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. (2022, Jan). Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World Journal of Gastroenterology, 28(1):140- 153. . (Impact factor = 5.28)
  5. Po-Yao Hsu, Tzu-Sheng Cheng, Shih-Chang Chuang, Wen-Tsan Chang, PoCheng Liang, Cheng-Ting Hsu, Yu-Ju Wei, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Yi-Hung Lin, Chih-Wen Wang, Ming-Yen Hsieh, Nai-Jen Hou, Meng-Hsuan Hsieh, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Chia-Yen Dai , Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Ming-Lung Yu (2022, Jan). Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. Cancer Medicine, 11(1):104-116..(Impact factor = 4.452)
  6. Ming-Ying Lu, Chun-Ting Chen, Yu-Lueng Shih , Pei-Chien Tsai, Meng-Hsuan Hsieh, Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang , Shu-Chi Wang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin , Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu , Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh , Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, Wen-Yu Chang. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. Scientific reports. 2021 Apr 20;11(1):8554..(Impact factor = 3.998)
  7. Tyng-Yuan Jang , Yu-Ju Wei, Ta-Wei Liu, Ming-Lun Yeh, Shu-Fen Liu , Cheng-Ting Hsu , Po-Yao Hsu , Yi-Hung Lin , Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen , Ching-Chih Lin , Pei-Chien Tsai , Shu-Chi Wang, Ching-I Huang , Zu-Yau Lin, Shinn-Cherng Chen , Wan-Long Chuang , Jee-Fu Huang , Chia-Yen Dai , Chung-Feng Huang , Ming-Lung Yu. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Scientific reports. 2021 Apr 14;11(1):8184. (Impact factor =3.998)
  8. Tyng-Yuan Jang, Yu-Ju Wei, Cheng-Ting Hsu, Po-Yao Hsu, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin, Pei-Chien Tsai, Shu-Chi Wang, Ching-I Huang, Ming-Lun Yeh, Zu-Yau Lin, Shinn-Cherng Chen, Wan-Long Chuang, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, Ming-Lung Yu. Serial Serologic Changes of Hepatitis D Virus in Chronic Hepatitis B Patients Receiving Nucleos(t)ides Analogues Therapy. Journal of Gastroenterology and Hepatology. 2020 Apr 4. (Impact factor = 3.437).
  9. Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Kuan-Yu Chen, Yu-Min Ko, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. Ribavirin Facilitates Early Viral Kinetics in Chronic Hepatitis C Patients Receiving daclatasvir/asunaprevir. Journal of Gastroenterology and Hepatology, 2020 Jan;35(1):151-156. (Impact factor = 3.437).
  10. Ta-Wei Liu, Pei-Chien Tsai, Ching-I Huang, Yi-Shan Tsai, Shu-Chi Wang, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Po-Cheng Liang, Yi-Hung Lin, Ming Yen Hsieh, Nai-Jen Hou, Chung-Feng Huang, Ming-Lun Yeh, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, MingLung Yu (2019, Jan). Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a realworld cohort. Journal of the Formosan Medical Association, 117(1):54-62. (Impact factor = 2.452).
  11. Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CI, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017 Oct;32(10):1754-1762. (Impact factor = 3.452)
  12. Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore). 2017 Jun;96(22):e6984. (Impact factor = 1.83)
  13. Ta-Wei Liua , Pei-Chien Tsai , Ching-I Huang , Yi-Shan Tsai , Shu-Chi Wang , Yu-Min Ko , Ching-Chih Lin , Kuan-Yu Chen , Po-Cheng Liang , Yi-Hung Lin , Ming-Yen Hsieh , Nai-Jen Hou , Chung-Feng Huang, Ming-Lun Yeh , Zu-Yau Lin , Shinn-Cherng Chen , Chia-Yen Dai , Wan-Long Chuang, Jee-Fu Huang , Ming-Lung Yu. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc. 2017 Apr 4. pii: S0929-6646(16)30477-6. (Impact factor = 2.018)
  14. Chung-Feng Huang, Ching-I Huang, Ming-Lun Yeh, Shu-Chi Wang, Kuan-Yu Chen, Yu-Min Ko, Ching-Chih Lin, Yi-Shan Tsai, Pei-Chien Tsai, Zu-Yau Lin , Shinn-Cherng Chen , Chia-Yen Dai , Jee-Fu Huang , Wan-Long Chuang, Ming-Lung Yu. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. Oncotarget. 2017 Mar 6. (Impact factor = 5.168)
  15. Chung-Feng Huang, Ching-I Huang, Ming-Lun Yeh, Shu-Chi Wang, Kuan-Yu Chen, Yu-Min Ko, Ching-Chih Lin, Yi-Shan Tsai, Pei-Chien Tsai, Zu-Yau Lin , Shinn-Cherng Chen , Chia-Yen Dai , Jee-Fu Huang , Wan-Long Chuang, Ming-Lung Yu. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. EBioMedicine. 2017 Feb;15:81-89. (Impact factor = 1.37)
  16. Huang JF, Ko YM, Huang CF, Yeh ML, Dai CY, Hsieh MH, Huang CI, Yang HL, Wang SC, Lin ZY, Chen SC, Yu ML, Chuang WL. 25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. Hepatol Res. 2017 Feb 22. (Impact factor = 2.602)
  17. Huang CF, Yeh ML, Huang CY, Tsai PC, Ko YM, Chen KY, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Medicine (Baltimore). 2016 Jul;95(27):e4157 (Impact factor = 1.63)
  18. Ko YM, Chang CY, Chiou SJ, Hsu FJ, Huang JS, Yang YL, Guh JY, Chuang LY. Ubiquitin C-terminal hydrolase-L5 is required for high glucose-induced transforming growth factor-β receptor I expression and hypertrophy in mesangial cells. Arch Biochem Biophys. 2013 Jul 15;535(2):177-86. (Impact factor = 2.935)
  19. Chen SC, Guh JY, Lin TD, Chiou SJ, Hwang CC, Ko YM, Chuang LY. Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells. Transl Res. 2011 Oct;158(4):214-24. (Impact factor = 2.986)

  20. Ko YM, Wu TY, Wu YC, Chang FR, Guh JY, Chuang LY. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells. J Ethnopharmacol. 2011 Oct 11;137(3):1283-90. (Impact factor = 3.014)
 

 Patent

  1.  Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor

       (1) Inventor：Ming-Lung Yu、Wan-Long Chuang、Jee-Fu Huang、Chia-Yen Dai、Yu-Min Ko

                   (2) Patent certificate：TW (I620933)、USA (7066209)、JP (11439689P)
 

 Journal Reviewer

  1. Reviewer, Phytomedicine. (Impact factor = 6.70. Ranked Q1, Top 3.5% in INTEGRATIVE & COMPLEMENTARY MEDICINE - SCIE).